$ USD
¥ 人民币
$ USD
€ 欧元
English
简体中文
English
繁体中文
Sign In / Sign up
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Menu
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Home
Oncology
Oncology
Oncology_Medical Halo Global Medical Oncology News_Oncology Drug Therapy News
舒尼替尼延长腺癌患者生存时间
2025-10-19 11:44:20
Check Details
吉非替尼治疗晚期胰腺癌
2025-10-19 11:44:20
Check Details
特罗凯(厄洛替尼)治疗晚期胰腺癌
2025-10-19 11:44:20
Check Details
奥拉帕利被授予胰腺癌患者的孤儿药称号
2025-10-19 11:44:20
Check Details
奥拉帕尼治疗胰腺癌患者的无进展生存期显著改善
2025-10-19 11:44:20
Check Details
奥拉帕利治疗BRCA突变转移性胰腺癌患者
2025-10-19 11:44:20
Check Details
特罗凯治疗转移性胰腺癌
2025-10-19 11:44:20
Check Details
胰腺癌治疗用药特罗凯(厄洛替尼)
2025-10-19 11:44:20
Check Details
胰腺癌靶向药物之奥拉帕尼
2025-10-19 11:44:20
Check Details
厄洛替尼与吉西他滨联用治疗胰腺癌
2025-10-19 11:44:20
Check Details
奥拉帕尼治疗BRCA1 /2突变的转移性胰腺癌
2025-10-19 11:44:20
Check Details
厄洛替尼在胰腺癌治疗中的应用
2025-10-19 11:44:20
Check Details
1
2
...
250
251
252
253
254
255
256
...
4156
4157
Category
Oncology
Hepatobiliary
dermatology
Endocrinology
Hematology
Andrology
Gynecology
Nephrology
Urology
Department of Infectious Diseases
Gastroenterology
Respiratory department
Neurology
Cardiology and Brain Department
ophthalmology
Psychiatry
Immunology Department
orthopedics
Burn Department
相关知识
1
Inluriyo (Imlunestrant): Oral SERD for ER+/HER2- Breast Cancer with ESR1 Mutations
2
Idelalisib: Oral PI3Kδ Inhibitor for Relapsed/Refractory Hematologic Malignancies
3
Lorlatinib (Lorviqua): Oral Targeted Therapy for ALK-Positive Advanced Non-Small Cell Lung Cancer
4
FDA Approves Ibrance for New Maintenance Indication in HR+/HER2+ Breast Cancer
5
FDA Approves Trodelvy for Two First-Line Indications, Redefining Advanced Triple-Negative Breast Cancer Care
6
Cabozantinib: A Pan-Targeted TKI in Modern Oncology Practice
7
Managing Amivantamab Infusion Reactions: A Clinical Guide for International Practice
8
Onset Timeline and Efficacy Assessment of Margetuximab plus Chemotherapy in HER2-Positive Metastatic Breast Cancer
9
Avutometinib Plus Defactinib: A Precision Therapy for KRAS-Mutant Recurrent Low-Grade Serous Ovarian Cancer
10
Vemurafenib (Zelboraf) Complete Medication Guide
11
Durvalumab Safety Profile: Managing Immune-Related Adverse Events (irAEs) in Clinical Practice
12
Zolbetuximab Combination Therapy: Global Efficacy and Safety Profile in CLDN18.2-Positive Advanced Gastric Cancer